Clinical Trial Update: Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study [Phase 3]

View source ↗

Summary

A Phase 3 extension study in Japan for the KEYNOTE-189 regimen evaluating pembrolizumab added to pemetrexed and platinum chemotherapy as first-line treatment of…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-Small-Cell Lung Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2020-06-11